Investor Presentaiton
Mirren Revenue FY18
ZAR 152m
1√2.9%
vs. LY
Coryx: Cough & Cold
Broncol: Cough & Cold
↑15%
Tab & syrup
market growth
(Cough & Cold)
"CORYX
Cold &fu relief
2 Efervescent tablets
4 day bang
190%
Syrup market
growth with no
BRONCOL
Cipla SA signs a definitive agreement to acquire 100% stake in Mirren (Pty) Ltd.
Deal is subject to SA Competition Commission Approval
Key
Transaction
Financials
OTC Growth in SA
11%
~300bps higher than
overall market
Cipla
Valuation Metrics
ZAR 450m
3x FY18 Sales
Ultimag: Mag & Zinc Supplement
Tensopyn: Pain Mgmt.
150%
BRONCOL
codeine
(Cough & Cold)
Tab & syrup
market growth
(Pain Mgmt)
Local manufacturing facility for liquids, OSD & Effervescent
Tab & syrup
market growth
(Mag & Zinc Supplement)
TENSOPYN
For TENSION PAN
TENSOPYN
130%
"ULTIMAG
ZINC
Synergies &
Capabilities
•
Play in the ZAR11Bn OTC market
Cipla OTC
Accelerate OTC business to reach ZAR 1Bn
18% of
14%
Expand presence in Pain, Cough & Cold
therapeutic area
Access to local liquid manufacturing facility
Cipla overall
YOY
business
Targeted Market
ZAR3bn
Investor Presentation: QIFY19
Cipla + Mirren
22%+ of
Cipla overall
business
Targeted Market
ZAR14bnView entire presentation